conduit for innovative science in cellular immunotherapies...

conduit for innovative science in cellular immunotherapies evolving in the Asian region and in particular China, for entry into the western regulatory system and ultimately western markets

It turns out that the east to west strategy in cellular immunotherapies has also been recognised by AstraZeneca. Reference is made to the article in FierceBiotech titled AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D, published 21 May 2024. AZ has recognised the explosion of innovation in China in the cellular space - think Car-T and CD19 - and are looking to leverage their expertise to globalize new medicines.

The topic of the article is in fact a validation of the AdCella strategy. So there is western competition in the cellular field in China [and Asia] but I suspect that AdAlta is early to the party and has its own unique leverage to employ i.e. the i-body platform that already has runs on the board in the Car-T space. The L word was also used by Professor Wilks in the collaboration announcement of 8 April 2024 where he talks about leveraging the advantages of the Australian biotech ecosystem.

Who can attract the very top ideas and most advanced clinical candidates? I think we will give AZ a good run for the money.